I would say the cost to capture patients in the UK may be higher...

I would say the cost to capture patients in the UK may be higher than Australia.

If Althea try to scale their business, they would be scaling their losses.

I guess this is what you get when you get a group of people with minimal pharma experience running a pharmaceutical business.

AGH's stock price is pretty much the lowest price it has ever been in the last 15 months for a reason. IMHO, I see the best solution is sacking the existing management and bringing in experienced pharma execs to replace the existing crew.